title: [Autologous peripheral blood stem cell transplantation for Japanese multiple myeloma patients: results of a feasibility study].
abstract: A feasibility study on high-dose therapy with autologous peripheral blood stem cell transplantation (HDT/PBSCT) was performed in Japanese patients with multiple myeloma (MM). Twenty evaluable patients younger than 65 years old with stage II/III MM were enrolled in this study. Three courses of VAD were used as initial chemotherapy. High-dose etoposide or cyclophosphamide followed by G-CSF was used for PBSCH, and 1.2-89.3 (median 23.4) x 106/kg of CD34+ cells were collected. Single (11 patients) or tandem (9 patients) HDT with melphalan (MEL) 200 mg/m2 or MEL 140 mg/m2 plus TBI 10 Gy were performed. The incidence of grade 4 toxicity (COG) was 10% and treatment-related mortality was 5%. Complete response and tumor reduction of more than 75% were obtained in 4 (21%) and 16 (84%) out of 19 patients, respectively. The actuarial 3-year overall survival (OS) and event-free survival (EFS) after PBSCT/HDT were 65.6% and 22.0%, respectively. The median EFS duration was 18 months. These preliminary results indicated that HDT/PBSCT is feasible for Japanese MM patients. A prospective randomized clinical trial will be required to assess the efficacy.
authors.affiliation: Department of Hematology, Dokkyo University School of Medicine.
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Nakamura
authors.forename: Hisashi
authors.initials: H
authors.lastname: Sakamaki
authors.forename: Harumi
authors.initials: H
authors.lastname: Mukai
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kojima
authors.forename: Junji
authors.initials: J
authors.lastname: Tomiyama
authors.forename: Shin-ichirou
authors.initials: S
authors.lastname: Mori
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Hiruma
authors.forename: Norihiko
authors.initials: N
authors.lastname: Nakamura
authors.forename: Shigeo
authors.initials: S
authors.lastname: Toyota
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Hamaguchi
authors.forename: Kazuo
authors.initials: K
authors.lastname: Dans
authors.forename: Kinuko
authors.initials: K
authors.lastname: Mitani
authors.forename: Kenji
authors.initials: K
authors.lastname: Saito
mesh_terms: D000328:Adult; D000368:Aged; D018952:Antigens, CD34; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005240:Feasibility Studies; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D007564:Japan; D008875:Middle Aged; D009101:Multiple Myeloma / Q000628:therapy*; D036102:Peripheral Blood Stem Cell Transplantation / Q000401:mortality; D015996:Survival Rate; D019172:Transplantation Conditioning; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D018952:Antigens, CD34; D016179:Granulocyte Colony-Stimulating Factor; D014750:Vincristine; D005047:Etoposide; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide